Volume 23, Number 3Bladder CancerImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsNeal D ShoreTreatment of non–muscle-invasive bladder cancer (NMIBC) is evolving, seeking new treatments to overcome the limitations of bacille Calmette-Guérin therapy and alternatives to radical cystectomy. Studies are currently evaluating the safety and efficacy of immune checkpoint inhibitors in combination with bacille Calmette-Guérin vs bacille Calmette-Guérin monotherapy for patients with high-risk NMIBC that is bacille Calmette-Guérin naive or recurrent after bacille Calmette-Guérin induction. We briefly summarize 4 studies that are evaluating intravenous immune checkpoint inhibitors (atezolizumab, durvalumab, and pembrolizumab) and 1 subcutaneous immune checkpoint inhibitor (sasanlimab). These studies may substantially change standard-of-care treatment for patients with high-risk NMIBC.immune checkpoint inhibitorsMonoclonal antibodiesClinical trialsnon-muscle invasive bladder neoplasms
Volume 5, Supplement 2SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Kenneth J PientaHoward M SandlerProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
Volume 5, Supplement 3SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Kenneth J PientaHoward M SandlerProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
Volume 6, Supplement 9SupplementThe Clinical Benefits of Dutasteride Treatment for LUTS and BPHClaus G RoehrbornBenign prostatic hyperplasiaLower urinary tract symptoms5-reductase inhibitorsDutasterideClinical trials